Management and outcome of muscle-invasive bladder cancer with clinical lymph node metastases. A nationwide population-based study in the bladder cancer data base Sweden (BladderBaSe)

References

• Capitanio U, Suardi N, Shariat SF, et al. Assessing the minimum number of lymph nodes needed at radical cystectomy in patients with bladder cancer. BJU Int. 2009;103(10):1359–1362.
   PubMed Web of Science ®Google Scholar
• Kluth LA, Black PC, Bochner BH, et al. Prognostic and prediction tools in bladder cancer: a comprehensive review of the literature. Eur Urol. 2015;68(2):238–253.
   PubMed Web of Science ®Google Scholar
• Kassouf W, Svatek RS, Shariat SF, et al. Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. Urol Oncol. 2013;31(4):480–486.
   PubMed Web of Science ®Google Scholar
• van Bruwaene S, Costello AJ, van Poppel H. Prognosis of node-positive bladder cancer in 2016. Minerva Urol Nefrol. 2016;68:125–137.
   PubMed Web of Science ®Google Scholar
• Milowsky MI, Nanus DM, Maluf FC, et al. Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. J Clin Oncol. 2009;27(25):4062–4067.
   PubMed Web of Science ®Google Scholar
• Dodd PM, McCaffrey JA, Herr H, et al. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J Clin Oncol. 1999;17(8):2546–2552.
   PubMed Web of Science ®Google Scholar
• Herr HW, Donat SM, Bajorin DF. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol. 2001;165(3):811–814.
   PubMed Web of Science ®Google Scholar
• Liu NW, Murray KS, Donat SM et al. The outcome of Post-Chemotherapy retroperitoneal lymph node dissection in patients with metastatic bladder cancer in the retroperitoneum. Bladder Cancer. 2019;5(1):13–19.
   PubMed Web of Science ®Google Scholar
• Galsky MD, Stensland K, Sfakianos JP, et al. Comparative effectiveness of treatment strategies for bladder cancer with clinical evidence of regional lymph node involvement. J Clin Oncol. 2016;34(22):2627–2635.
   PubMed Web of Science ®Google Scholar
• Meijer RP, Mertens LS, van Rhijn BW, et al. Induction chemotherapy followed by surgery in node positive bladder cancer. Urology. 2014;83(1):134–139.
   PubMed Web of Science ®Google Scholar
• Al-Husseini MJ, Kunbaz A, Saad AM, et al. Trends in the incidence and mortality of transitional cell carcinoma of the bladder for the last four decades in the USA: a SEER-based analysis. BMC Cancer. 2019;19(1):46.
   PubMedGoogle Scholar
• Marqueen KE, Waingankar N, Sfakianos JP et al. Early mortality in patients with Muscle-Invasive bladder cancer undergoing cystectomy in the United States. JNCI Cancer Spectr. 2018;2(4):pky075.
   PubMed Web of Science ®Google Scholar
• Williams SB, Huo J, Chamie K, et al. Underutilization of radical cystectomy among patients diagnosed with clinical stage T2 Muscle-invasive bladder cancer. Europ Urol Focus. 2017;3(2–3):258–264.
   PubMedGoogle Scholar
• Haggstrom C, Liedberg F, Hagberg O, et al. Cohort profile: The Swedish National Register of Urinary Bladder Cancer (SNRUBC) and the Bladder Cancer Data Base Sweden (BladderBaSe). BMJ Open. 2017;7:e016606.
   PubMed Web of Science ®Google Scholar
• Fedeli U, Fedewa SA, Ward EM. Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. J Urology. 2011;185(1):72–78.
   PubMed Web of Science ®Google Scholar
• Soria F, Moschini M, Korn S, et al. How to optimally manage elderly bladder cancer patients? Transl Androl Urol. 2016;5(5):683–691.
   PubMed Web of Science ®Google Scholar
• Mistretta FA, Mazzone E, Knipper S, et al. Contemporary trends of pelvic lymph node dissection at radical cystectomy for urothelial carcinoma of urinary bladder and associated cancer specific mortality and complications: comparison between octogenarian versus younger patients. Cancer Epidemiol. 2019;59:135–142.
   PubMed Web of Science ®Google Scholar
• Dash A, Galsky MD, Vickers AJ, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer. 2006;107(3):506–513.
   PubMed Web of Science ®Google Scholar
• Mertens LS, Meijer RP, Kerst JM, et al. Carboplatin based induction chemotherapy for nonorgan confined bladder cancer–a reasonable alternative for cisplatin unfit patients? J Urol. 2012;188(4):1108–1113.
   PubMed Web of Science ®Google Scholar
• Stenehjem DD, Tran D, Nkrumah MA, et al. PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer. Onco Targets Ther. 2018;11:5973–5989.
   PubMed Web of Science ®Google Scholar
• Klaassen Z, DiBianco JM, Jen RP, et al. Female, black, and unmarried patients are more likely to present with metastatic bladder urothelial carcinoma. Clin Genitourin Cancer. 2016;14(5):e489–e92.
   PubMedGoogle Scholar
• Niu Q, Lu Y, Wu Y, et al. The effect of marital status on the survival of patients with bladder urothelial carcinoma: a SEER database analysis. Medicine. 2018;97(29):e11378.
   PubMed Web of Science ®Google Scholar
• Linder G, Sandin F, Johansson J, et al. Patient education-level affects treatment allocation and prognosis in esophageal- and gastroesophageal junctional cancer in Sweden. Cancer Epidemiol. 2018;52:91–98.
   PubMed Web of Science ®Google Scholar
• Merrill RM, Johnson E. Benefits of marriage on relative and conditional relative cancer survival differ between males and females in the USA. J Cancer Surviv. 2017;11(5):578–589.
   PubMed Web of Science ®Google Scholar
• Galsky MD, Stensland KD, et al. Effectiveness of adjuvant chemotherapy for locally advanced bladder cancer. J Clin Oncol. 2016;34(8):825–832.
   PubMed Web of Science ®Google Scholar
• Nieuwenhuijzen JA, Bex A, Meinhardt W, et al. Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer. J Urology. 2005;174(1):80–85.
   PubMed Web of Science ®Google Scholar
• de Vries RR, Nieuwenhuijzen JA, Meinhardt W, et al. Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only. Eur J Surg Oncol. 2009;35(4):352–355.
   PubMed Web of Science ®Google Scholar
• Zargar-Shoshtari K, Zargar H, Lotan Y, et al. A Multi-Institutional analysis of outcomes of patients with clinically node positive urothelial bladder cancer treated with induction chemotherapy and radical cystectomy. J Urol. 2016;195:53–59.
   PubMed Web of Science ®Google Scholar
• Alfred Witjes J, Lebret T, Compérat EM, et al. Updated 2016 EAU guidelines on Muscle-invasive and metastatic bladder cancer. Eur Urol. 2017;71(3):462–475.
   PubMed Web of Science ®Google Scholar
• Pradere B, Thibault C, Vetterlein MW, et al. Peri-operative chemotherapy for muscle-invasive bladder cancer: status-quo in 2017. Transl Androl Urol. 2017;6:1049–1059.
   PubMed Web of Science ®Google Scholar
• Roberts JT, von der Maase H, Sengeløv L, et al. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. Ann Oncol. 2006;17(Suppl_5):v118–22.
   PubMedGoogle Scholar
• von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602–4608.
   PubMed Web of Science ®Google Scholar